The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer A Literature Review

被引:165
作者
Hirsch, Fred R. [1 ]
Spreafico, Anna [2 ]
Novello, Silvia [3 ]
Wood, Mary Dugan [4 ]
Simms, Lorinda [5 ]
Papotti, Mauro [6 ]
机构
[1] Univ Colorado, Ctr Canc, Aurora, CO 80045 USA
[2] San Raffaele Sci Univ Inst, Dept Oncol, Milan, Italy
[3] Univ Turin, Thorac Oncol Unit, San Luigi Hosp, Turin, Italy
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Eli Lilly Canada, Toronto, ON, Canada
[6] Univ Turin, Dept Clin & Biol Sci, Turin, Italy
关键词
Non-small cell lung cancer; Histology; Chemotherapy; Prognostic; Predictive;
D O I
10.1097/JTO.0b013e318189f551
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The importance of non-small cell lung cancer (NSCLC) histologic subtype has increased during the last few decades because of an unprecedented shift in epidemiology and an increasing number of target-specific chemotherapeutic agents. This review examined histology as a potential prognostic and/or predictive factor of clinical outcomes in advanced NSCLC. Methods: Literature searches of articles from 1982 to 2007 were conducted. We identified publications detailing phase II or III studies, retrospective analyses, and meta-analyses that reported a statistically significant prognostic or predictive role for histology. Results: Of 408 publications identified, II reported a prognostic association between histology and clinical outcomes, and 7 suggested that histologic subtype was predictive of outcomes in patients with advanced NSCLC treated with specific cytotoxic chemotherapy regimens. Fourteen publications reported histology was prognostic and/or predictive in patients treated with epidermal growth factor receptor inhibitors. Inadequate data collection, test methodology, or Study design-including insufficient sample size, misclassified samples, and grouping of histologic subtypes for analysis-may have obscured the interpretation of the role of histology in many of the Studies. Conclusions: Although differences in Study design and analyses make definitive Conclusions difficult, evidence suggests that histology may be prognostic or predictive of clinical efficacy outcomes. To determine which patients would benefit from specific treatments and to further understand the role of histology, future studies should focus on establishing a definitive histologic diagnosis, and should include an analysis of histologic subtypes and efficacy outcomes.
引用
收藏
页码:1468 / 1481
页数:14
相关论文
共 98 条
  • [1] [Anonymous], 2007, Journal of Thoracic Oncology
  • [2] Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis
    Ardizzoni, Andrea
    Boni, Luca
    Tiseo, Marcello
    Fossella, Frank V.
    Schiller, Joan H.
    Paesmans, Marianne
    Radosavljevic, Davorin
    Paccagnella, Adriano
    Zatloukal, Petr
    Mazzanti, Paola
    Bisset, Donald
    Rosell, Rafael
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (11) : 847 - 857
  • [3] RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer
    Bepler, Gerold
    Kusmartseva, Irina
    Sharma, Swati
    Gautam, Ashish
    Cantor, Alan
    Sharma, Anupama
    Simon, George
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) : 4731 - 4737
  • [4] Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
    Bhattacharjee, A
    Richards, WG
    Staunton, J
    Li, C
    Monti, S
    Vasa, P
    Ladd, C
    Beheshti, J
    Bueno, R
    Gillette, M
    Loda, M
    Weber, G
    Mark, EJ
    Lander, ES
    Wong, W
    Johnson, BE
    Golub, TR
    Sugarbaker, DJ
    Meyerson, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) : 13790 - 13795
  • [5] The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer
    Billingham, LJ
    Cullen, MH
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (12) : 1671 - 1675
  • [6] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
    Cappuzzo, F
    Hirsch, FR
    Rossi, E
    Bartolini, S
    Ceresoli, GL
    Bemis, L
    Haney, J
    Witta, S
    Danenberg, K
    Domenichini, I
    Ludovini, V
    Magrini, E
    Gregorc, V
    Doglioni, C
    Sidoni, A
    Tonato, M
    Franklin, WA
    Crino, L
    Bunn, PA
    Varella-Garcia, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09): : 643 - 655
  • [7] Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
    Cappuzzo, F
    Magrini, E
    Ceresoli, GL
    Bartolini, S
    Rossi, E
    Ludovini, V
    Gregorc, V
    Ligorio, C
    Cancellieri, A
    Damiani, S
    Spreafico, A
    Paties, CT
    Lombardo, L
    Calandri, C
    Bellezza, G
    Tonato, M
    Crinò, L
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15): : 1133 - 1141
  • [8] Cell type accuracy of bronchial biopsy specimens in primary lung cancer
    Cataluna, JJS
    Perpina, M
    Greses, JV
    Calvo, V
    Padilla, JD
    Paris, F
    [J]. CHEST, 1996, 109 (05) : 1199 - 1203
  • [9] A RANDOMIZED TRIAL OF ALTERNATING CHEMOTHERAPY VERSUS BEST SUPPORTIVE CARE IN ADVANCED NON-SMALL-CELL LUNG-CANCER
    CELLERINO, R
    TUMMARELLO, D
    GUIDI, F
    ISIDORI, P
    RASPUGLI, M
    BISCOTTINI, B
    FATATI, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (08) : 1453 - 1461
  • [10] ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
    Ceppi, P.
    Volante, M.
    Novello, S.
    Rapa, I.
    Danenberg, K. D.
    Danenberg, P. V.
    Cambieri, A.
    Selvaggi, G.
    Saviozzi, S.
    Calogero, R.
    Papotti, M.
    Scagliotti, G. V.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (12) : 1818 - 1825